TABLE 9.1 Health Benefits and Expenditures Associated with Various Vaccine Candidates: Central Analysis
|
Pathogen (Target Population)
|
Vaccine Envisaged
|
Annualized Present Value of Potential Health Benefits (IME Units)
|
Annualized Present Value of Expenditures on Vaccines Necessary to Achieve Potential Health Benefits ($ millions)
|
|
Dengue virus
(Infants and children in endemic areas; travelers to endemic areas)
|
Attenuated live vector virus containing gene for broadly cross-reacting protective antigen
|
9,558
|
242
|
|
Escherichia coli
(enterotoxigenic)
(Infants < 6 months)
|
A combination of purified colonization factor antigens and possibly other antigens
|
126,454
|
722
|
|
Genetically engineered attenuated strains
|
145,260
|
69
|
|
Hemophilus influenzae type b
(Infants)
|
Conjugated polysaccharide
|
210,943
|
527
|
|
Hepatitis A virus
(Susceptibles of all ages; routine for preschool children)
|
Attenuated live virus
|
15,112
|
1,058
|
|
Polypeptide recombinant vaccine produced in yeast
|
14,392
|
4,029
|
|
Hepatitis B virus
(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations)
|
Polypeptide produced by recombinant DNA technology
|
213,192
|
8,859
|
|
Japanese encephalitis virus
(Children in epidemic and and endemic areas; foreign visitors to epidemic regions)
|
Inactivated virus produced in cell culture
|
3,232
|
614
|
